Industry Pharmaceuticals Founded 1851 | Defunct 2009 Acquisition date November 2009 | |
 | ||
Former type Subsidiary of Merck & Co. Key people Fred Hassan
Final CEO & Chairman Revenue US$ 18.502 billion (2008) Net income US$ 1.903 billion (2008) Headquarters Kenilworth, New Jersey, United States Founder Ernst Christian Friedrich Schering Subsidiaries Organon International, Intervet Inc Parent organization P.T. Schering Plough Indonesia | ||
Schering plough
Schering-Plough Corporation was a United States-based pharmaceutical company. It was originally the US subsidiary of the German company Schering AG, which was founded in 1851 by Ernst Christian Friedrich Schering. As a result of nationalization it became an independent company. In 1971, the Schering Corporation merged with Plough (founded by Memphis area entrepreneur Abe Plough in 1908) to form Schering-Plough. On November 4, 2009 Merck & Co. merged with Schering-Plough with the new company taking the name of Merck & Co.
Contents
- Schering plough
- 2006 ceo innovation lecture fred hassan schering plough corp
- Pharmaceuticals and consumer products
- Coopers Animal Health
- Intervet
- Merck Animal Health MSD Animal Health
- Prescription products
- Over the counter products
- Veterinary products
- Exercise drug
- Collaborative research
- Controversy
- References
Schering-Plough manufactured several pharmaceutical drugs, the most well-known of which were the allergy drugs Claritin and Clarinex, an anti-cholesterol drug Vytorin, and a brain tumor drug Temodar. These are now available from Merck & Co.
Schering Plough also owned and operated the major foot care brand name Dr. Scholl's and the skin care line Coppertone. These also became a part of the new company.
As of June 2005, Schering-Plough had 1.4% market share in the U.S., placing it seventeenth in the top twenty pharmaceutical corporations by sales compiled by IMS Health.
Schering-Plough was a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), a membership which is also maintained by the new Merck & Co.
2006 ceo innovation lecture fred hassan schering plough corp
Pharmaceuticals and consumer products
Schering was founded in 1851 by Ernst Christian Friedrich Schering as Schering AG in Germany.
Following the entry of the United States into World War II in 1941, U.S. President Franklin Delano Roosevelt ordered Schering AG's U.S. assets be seized. These became the Schering Corporation. The company was placed under a government administratorship until 1952, when it was released and its assets sold to the private sector.
In 1957, Schering acquired White Laboratories.
Plough, Incorporated was founded by the Memphis, Tennessee area entrepreneur Abe Plough (1892–1984) in 1908 [1]. He borrowed $125 from his father to start the business at age sixteen. As a one-man business, he mixed "Plough's Antiseptic Healing Oil," a "sure cure for any ill of man or beast," and sold it off a horse-drawn buggy.
Plough's acquisitions included St Joseph's Aspirin for children, Maybelline cosmetics, and Coppertone skin care products. Plough also had a broadcasting division, operating radio stations in Atlanta, Georgia; Baltimore, Maryland; Boston, Massachusetts; Chicago, Illinois; and Memphis, Tennessee.
In 1971, the Schering Corporation merged with Plough, Inc. At the time of the merger, Abe Plough became Chairman of the combined company.
In 2000, Schering Plough bought a new campus in Summit, New Jersey from Novartis.
On March 9, 2009 it was announced that Schering-Plough and Merck were to merge. On November 4, 2009 Schering-Plough merged with Merck & Co. and through a reverse merger Merck became a subsidiary of Schering-Plough, which renamed itself Merck.
Coopers Animal Health
One of Schering-Plough's plants, in Upper Hutt, New Zealand was the largest single site for the production of veterinary vaccines in the world. This was primarily because New Zealand's isolation has formed a natural quarantine, leaving the country free of rabies, foot and mouth, scrapie, bovine spongiform encephalopathy, and many other livestock diseases. It formerly had echinococcosis, but this has been eradicated. The site was known locally as Coopers Animal Health, a trademark which originated in the 1850s with a British company, Cooper & Newphews; the Coopers brand name was still in use by Schering-Plough in Australia, but not elsewhere.
Intervet
On 12 March 2007, Schering-Plough Corp. purchased Organon International, the drug unit of Netherlands-based Akzo Nobel, for $14.4 billion, giving the US pharmaceutical company an array of women's health products and numerous late-stage pipelines of experimental medicines.
Organon itself was founded in 1923 by Dr. Saal van Zwanenberg, the president of Zwanenberg’s Slachterijen en Fabrieken. The company is housed at Zwanenberg’s premises in Oss, the Netherlands. By August 21, 2008, Famvir (famciclovir) was marketed by Schering-Plough; formerly it was marketed by Novartis.
As a result of the acquisition of Organon BioSciences, Schering-Plough bolstered its animal health business with the Akzo Nobel subsidiary Intervet, obtained control of the active pharmaceutical ingredient manufacturer, Diosynth and gained access to human vaccine production through the subsidiary Nobilon. The three companies comprising Organon BioSciences were—Organon, Diosynth, and Intervet. HomeAgain continues to use the Intervet name owned by Merck.
Merck Animal Health, MSD Animal Health
After the merger of Schering-Plough with Merck the animal health division was still known as Intervet/Schering-Plough Animal Health. A merger of Merial and Intervet/Schering-Plough was planned in 2010, but was abandoned in March 2011. On June 29, 2011, the company announced that the animal health division would now be known as Merck Animal Health in the United States and Canada; it is now called MSD Animal Health elsewhere in the world.
Prescription products
Over-the-counter products
Veterinary products
Exercise drug
Schering-Plough also received much publicity for a drug AICAR which mimics the effects of exercise, having especially potent effects when used alongside another drug GW1516 developed by GlaxoSmithKline.
Collaborative research
In addition to internal research and development activities Schering-Plough was also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment was the InnoMed PredTox.
Controversy
In 2004, Schering-Plough was accused of marketing gimmicks and payoffs to doctors for prescribing the company's pharmaceutical products.
Schering-Plough entered into a Consent Decree with the FDA on March 6, 2002 due to manufacturing issues with its albuterol inhaler. It was ordered to pay $500 Million US dollars to the US Treasury.